Keefe Bruyette lowered the firm’s price target on MetLife (MET) to $98 from $100 and keeps an Outperform rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MET:
- MetLife price target lowered to $95 from $96 at Barclays
- MetLife Reports Strong 2024 Earnings Growth
- MetLife Earnings Call: Positive Outlook Amid Challenges
- Optimistic Outlook: MetLife’s Strong Recovery and Future Growth Potential Supports Buy Rating
- Positive Outlook for MetLife Stock Amid Strategic Share Repurchases and Improved Investment Income